At a glance
ClinicalIndex Comparison Record- ✓ECOG Performance Status 0 or 1
- ✓Life expectancy at least 12 weeks
- ✓Locally advanced, recurrent, or metastatic malignancy ineligible for definitive local therapy
- ✓No prior checkpoint inhibitor therapy (CPI-naive)
- ✕Pregnancy or breastfeeding
- ✕Significant cardiovascular disease
- ✕Known clinically significant liver disease
- ✕Poorly controlled Type 2 diabetes mellitus
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Tiragolumab and Atezolizumab IV FDC for PD-L1-selected Solid Tumors. Completed, enrolled 64 participants across 32 sites in 9 countries.
Signals
Detailed Summary
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected solid tumors whose disease is locally advanced, recurrent, or metastatic and for whom an investigational agent in combination with an anti-PD-L1 antibody is considered an acceptable treatment option.
Study Details
Timeline
Arms & Interventions
Participants will receive tiragolumab and atezolizumab as an intravenous fixed dose combination (IV FDC) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Interventions
Intravenous fixed dose combination (IV FDC) of tiragolumab 600 mg and atezolizumab 1200 mg once every 3 weeks (Q3W).